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ADR AND DRUG TESTING IN
PROFESSIONAL TENNIS: AN EFFECTIVE
DOUBLES TEAM?
RYAN M. RODENBERG*

&

KATIE A. FEATHERSTON**

I. INTRODUCTION

The sport of professional tennis is often described as a conflicted bowl of
alphabet soup. Specifically, the number of acronyms with their hand in the
sport is high - "WTA" (Women's Tennis Association), "ATP" (Association of
Tennis Professionals), "ITF" (International Tennis Federation), "USTA"
(United States Tennis Association), "LTA" (Lawn Tennis Association), etc. If
the big three sports management firms (Octagon, SFX Sports Group, and
IMG) are added, there are even more. With interests that are different in scope
and purpose, a unified alternative dispute resolution ("ADR") mechanism to
oversee drug testing and enforcement in professional tennis for both women
and men would seem illusory, but it is not. The Tennis Anti-Doping Program
("Program") is a reality. The three primary governing bodies of professional
tennis worldwide, the ITF, the ATP, and the WTA, have signed on to the
Program, partnering to make the Program an effective, yet understandable,
ADR vehicle for protecting the integrity of professional tennis competition.
This article will: (i) summarize the Program; (ii) discuss a small number of
recent decisions impacting the Program; and (iii) explain why ADR, as
implemented in the Program, is appropriate for professional tennis.
II. OVERVIEW OF THE TENNIS ANTI-DOPING PROGRAM
A. Specific Aspects of the Program.
The Program, created jointly by the ATP, the WTA, and the ITF in 1993,
* Associate General Counsel, Octagon, McLean, Virginia. Mr. Rodenberg is a graduate of
Creighton University and the University of Washington School of Law.
**J.D. Candidate 2006, Marquette University Law School, Milwaukee, Wisconsin; Sports Law
Certificate Candidate 2006, National Sports Law Institute, Milwaukee, Wisconsin.
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is self-described as a "comprehensive and internationally recognized drugtesting program."' The goals of the Program are to "ensure equal and fair
competition on the field of play [and] protect the health of professional tennis
players." 2 The Program achieves uniformity by testing for all banned
substances on the World Anti-Doping Agency ("WADA") list and by
conducting tests in accordance with the WADA Code. 3 General categories of
substances that are banned at all times (in-competition and out-of-competition)
include: (i) anabolic agents; (ii) hormones and related substances; (iii) beta-2
agonists; (iv) agents with anti-estrogenic activity; and (v) diuretics and other
masking agents. 4
Substance categories prohibited in-competition only
include: (i) stimulants; (ii) narcotics; (iii) cannabinoids; and (iv)
glucocorticosteriods. 5 The Program also bars artificial oxygen transfer
enhancements (e.g. blood doping), chemical or physical manipulation of the
urine or blood to be tested, and gene doping. 6 Like virtually all other drug
testing procedures in sports, the Program does permit therapeutic use
exemptions, whereby a player can request permission to use, for documented
7
medical reasons, substances whose use would otherwise be prohibited.
In 2004, the most recent year testing numbers are available, the Program
tested 664 male and female tennis players a total of 1501 times, a number that
includes 1479 "in-competition" tests. 8 Among male players ranked in the top
fifty of the ATP computer rankings, each such player was tested an average of
4.9 times in 2004. 9 The Program is administered for the ITF, the WTA, and
the ATP by International Drug Testing Management ("IDTM") in Sweden, a
company that also administers drug testing for a number of other sports
governing bodies, including track and field's International Association of
Athletics Federations ("IAAF").10

1. TENNIs ANTI-DOPING PROGRAM 2005 INFORMATION SHEET (2005), available at
http://www.atptennis.atponline.net/en/common/Tracklt.asp?file=/en/antidoping/English.pdf.
2. Id.
3. Id.
4. VII The Code, 7.06 Tennis Anti-Doping Program 2005, in ATP OFFICIAL RULE BOOK, 167-70
(2005), http://www.atptennis.com/enlcommon/Tracklt.asp?file-/en/antidoping/rules.pdf
[hereinafter
The Code]. See also Appendix A, WTA Tour Tennis Anti-Doping Program2005, in 2005 WTA TOUR
OFFICIAL RULEBOOK 263-314 (2005), available at http://www.wtatour.com/global/pdfs/
shared/thewtatour/officialrules/rules.pdf.
5. The Code, supra note 4.
6. Id.
7. Id. at 7.06E
8. TENNIS ANTI-DOPING PROGRAM 2005 INFORMATION SHEET, supra note 1.
9. Id.
10. Id.
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Like all ADR procedures, the Program's jurisdiction over players is based
in contract. At the start of each year, male and female professional tennis
players are required, prior to competing in any WTA, ATP, or ITF
tournament, to sign a consent form whereby the signee agrees to be bound by
all applicable rules, including the Program." As an example, the ATP consent
form includes the following relevant language:
I consent and agree to comply with and be bound by all of the
provisions of the [ATP Rules], including . . . the Anti-Doping

Program.... I also consent and agree that any dispute arising out of
any decision made by the Anti-Doping Tribunal, or any dispute arising
under or in connection with the Anti-Doping Program, after
exhaustion of the Anti-Doping Program's Anti-Doping Tribunal
process and any other proceedings expressly provided for in the
Program, shall be submitted exclusively to the Appeals Arbitration
Division of the Court of Arbitration for Sport ("CAS") for final and
binding arbitration in accordance with the Code of Sports-Related
Arbitration. The decisions of CAS shall be final, non-reviewable,
non-appealable and enforceable.12

B. ADR Procedurefor a Doping Offense under the Program.
The Program outlines the procedures available to a player if her or his
doping test is positive. 13 The Program's dispute resolution procedures provide
an athlete who is suspected of doping with "fair and due process."' 4 All
players are presumed innocent and are allowed to continue playing tennis until
15
a decision is rendered.
When it is clear that a doping offense has occurred, the Administrator of
Rules of the applicable tennis governing body appoints an Anti-Doping
Tribunal ("Tribunal") to conduct the dispute resolution proceedings. 16 The
player suspected of doping is sent a written notice, which includes: (i) a
summary of the doping offense, including the suspected prohibited substances
found in the player's sample and the factual background relied upon for the

11. See, e.g., Consent Form, in ATP 2005 OFFICIAL RULEBOOK 166
http://www.atptennis.atponline.net/en/common/Tracklt.asp?file=/en/antidoping/rules.pdf.
12. Id.
13. The Code, supra note 4.
14. TENNIS ANTI-DOPING PROGRAM 2005 INFORMATION SHEET, supra note 1.
15. Id.
16. The Code, supra note 4, at 7.06 K.l.a.
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doping charge; (ii) a list of the possible consequences the player will face
because of the doping offense; and (iii) a statement notifying the player of her
or his right to have the doping offense disputed at a hearing.17 If the player
chooses to avail her or himself of dispute resolution procedures, then she or he
must submit a written request to the Administrator of Rules within ten days of
1
receipt of the notice. 8
If the player fails to provide such written notice, she or he waives the right
19
to a hearing and accepts the consequences outlined in the written notice.
The Chairman of the Tribunal will then release a statement announcing the
doping offense and listing the player's punishment. 20 The same statement will
be released if, at any time, the player admits the doping offense. 21 In the case
of a player admitting a doping offense, the player and the tennis governing
22
body may submit suggestions to the Tribunal for the player's punishment.
If the player chooses to have a hearing concerning the doping offense, she
or he will be notified of the identities of the members of the Tribunal and be
allowed to express any concerns about the members chosen to hear the
dispute. 2 3 The members of the Tribunal not being objected to by the player
will rule on the legitimacy of the player's objection. 24 If the player's objection
to a Tribunal member is deemed legitimate, the Administrator of Rules will
25
appoint a replacement member.
Within twenty-one days of the player's receipt of notice of the doping
offense, the Chairman of the Tribunal meets in person or by telephone with the
applicable tennis governing body, the player, and both parties' legal
representatives. 26 At this meeting, the date of the hearing, the dates when the
parties will have to submit briefs outlining their arguments, and the dates when
the parties will have to exchange witness lists are determined. 27 In addition,
the Chairman makes any other necessary orders, including orders concerning
28
document production.

17. Id.
18. Id. at 7.06 K.iLb.
19. Id.
20.
21.
22.
23.

Id.
Id. at 7.06 K.1.c.
Id.
Id. at 7.06 K.1.d.

24.
25.
26.
27.

Id.
Id. at 7.06 K. 1.e.
Id. at 7.06 K.l1f.
Id.

28. Id.
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The player need not be present at the hearing and can be represented by
counsel. 29 The procedure for the hearing is at the discretion of the Chairman
of the Tribunal, as long as each party is allowed to present its case, including
calling and questioning witnesses. 30 The tennis governing body may have the
hearing transcribed if it so wishes. 3 1 The hearing is conducted in English, but
an interpreter will be provided at the player's request. 32 The tennis governing
body is responsible for the costs associated with the Tribunal and the
33
hearing.
The tennis governing body has the burden of proof concerning the
34
existence of the doping offense.

The standard of proof shall be whether [the applicable tennis
governing body] has established the commission of the alleged
Doping Offense to the comfortable satisfaction of the Anti-Doping
Tribunal, bearing in mind the seriousness of the allegation that is
made. This standard of proof in all cases is greater than a mere
35
balance of probability but less than proof beyond a reasonable doubt.
If the player is charged with the burden of rebutting a presumption of
guilt, the standard of proof is beyond a reasonable doubt. 36 The hearing is not
governed by judicial rules of evidence; therefore, either party is allowed to
37
establish facts by "any reliable means."
At the conclusion of the hearing, the Tribunal deliberates in private. 3 8 An
opinion that a doping offense has occurred must be unanimous, and all
members of the Tribunal must participate in the decision. 39 If the consensus is
that the player committed the doping offense, the Tribunal determines the
appropriate consequences according to the guidelines provided in the
Program. 40 The decision is issued in writing and includes: (i) what doping
offense, if any, has occurred; (ii) the applicable consequences; and (iii) the

29. Id. at 7.06 K.2.b.
30.
31.
32.
33.
34.

Id. at 7.06
Id. at 7.06
Id. at 7.06
Id. at 7.06
Id. at 7.06

K.2.c.
K.2.d.
K.2.e.
K.5.c.
K.3.a.

35. Id.
36. Id. at 7.06 K.3.b.
37. Id. at 7.06 K.4.
38. Id. at 7.06 K.5.a.
39. Id.
40. Id.
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player's right to appeal. 4 1
If the player is found not guilty of the doping offense, the decision is not
published.4 2 The player's identity remains confidential. 43 However, if the
player is found guilty of a doping offense, the decision is published within
44
twenty days.
45
The player does have a right to appeal the Tribunal's decision.
Nonetheless, the decision of the Tribunal will remain in effect during the
appeal process. 46 An appeal concerning any part of the decision of the
Tribunal may be appealed to the CAS within twenty-one days of the receipt of
the Tribunal's decision. 47 The appeal is subject to the CAS rules concerning
Appeal Arbitration Hearings. 48 If the CAS chooses to accept the appeal, it
will conduct a de novo hearing of the doping issue, and its decision replaces
any decision of the Tribunal. 49 There is no further right of appeal for any of
50
the parties from the CAS decision.
III. SAMPLE DECISIONS AND DEVELOPMENTS

A. Bohdan Ulihrach.
The case of male tennis player Bohdan Ulihrach ("Ulihrach") provides a
thorough examination of the ADR procedure when a doping offense occurs in
professional tennis. Ulihrach, a Czech, has been playing professional tennis
since 1994. 5 1 In October 2002, while participating in the Kremlin Cup in
Moscow, Russia, Ulihrach submitted to a drug test. 52 In December 2002, he
received written notice from the Administrator of Rules of the ATP that the
sample taken in Moscow showed illegal levels of Noranderosterone and

41. Id. at 7.06 K.5.b.
42. Id. at 7.06 K.5.d.
43. Id.
44. Id.
45. Id. at 7.06 0.1.
46. Id.
47. Id. at 7.06 0.2.
48. Id.
49. Id. at 7.06 P.1.
50. Id. at 7.06 P.3.
51. Decision of the ATP Tour Anti-Doping Tribunal on the Appeal of Bohdan Ulihrach, 1
(2003),
http://www.atptennis.atponline.net/en/common/Tracklt.asp?file=/en/antidoping/
PLAYER-decision_Ulihrach.pdf.
52. Id. at 4.
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54
Noretiocholanolone. 5 3 Ulihrach requested a hearing before the Tribunal.
The hearing was held in April 2003. 55 Ulihrach alleged that he did not take a
prohibited substance and that he did not know the origin of the illegal levels of
the substances. 56 He argued that the Tribunal should not apply strict liability
or, in the alternative, it should consider his lack of intent and fault when
57
considering the consequences of the doping offense.
Like most anti-doping programs in sports, the Program follows a rule of
strict liability, meaning that regardless of intent or fault, the presence of a
prohibited substance in a player's sample is evidence of a doping offense. 58 In
the case of Ulihrach, the Tribunal was not willing to stray from this rule, and
even though Ulihrach claimed that he did not ingest a prohibited substance and
that he did not know what caused the illegal levels in his sample, he was
suspended from professional tennis for a period of two years. 59 Additionally,
Ulihrach was required to forfeit all prize money and ranking points earned at
the tournament where the doping offense occurred and any prize money and
60
ranking points earned after that tournament.
In May 2003, Ulihrach submitted an appeal to the CAS, 6 1 but before CAS
could rule on whether or not to grant the appeal, the Tribunal decided to
reopen Ulirach's case. 62 Between May and June 2003, the ATP learned of an
electrolyte product being distributed by ATP trainers to its players that could
63
possibly be the source of the prohibited substance in Ulihrach's sample.
Between August 2002 and May 2003, twenty-seven ATP players showed
varying levels of nandrolone metabolites in their samples, one of whom was
Ulihrach. 64 Because of the make-up of the test results, the ATP determined
that the same electrolyte substance had to be causing the increased levels of
nandrolone in all of these cases. 65 It was also determined that PAN

53. Id. at 5-6.
54. Id. at 7.
55.
56.
57.
58.

See id.
Id. at 17.
Id.
Id. at 18 (citing The Code Rules C. La, C.3).

59. Id. at

44.

60. Id. at 45.
61. Decision of the ATP Tour Anti-Doping Tribunal on the Re-opening of the HearingAppeal of
Bohdan Ulihrach,
2 (2003), http://www.atptennis.atponline.net/en/common/Tracklt.asp?file=/
en/antidoping/decision.pdf
62. Id. at

6.

63. Id. at
64. Id.
65. Id. at

3(6).
5.
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Pharmaceutical, a supplement manufacturer, had been selling products that
were 700% stronger than its labels stated. 66 The electrolyte product being
distributed may have been produced by PAN. 67 Ulihrach had been given the
electrolyte tablet by ATP trainers at the Moscow tournament and another
chose to exonerate
tournament in late September 2002.68 The Tribunal
69
facts.
discovered
newly
these
of
Ulihrach because
Applying the doctrine of equitable estoppel, 70 the Tribunal ruled that the
burden of proof shifted to the ATP. 71 The ATP was unable to produce
evidence proving that the illegal levels in Ulihrach's sample did not come
from the electrolyte product. 72 Additionally, the Tribunal ruled that the ATP
was precluded from enforcing its strict liability rules because its trainers were
the source of the prohibited substance. 73 Therefore, Ulihrach was reinstated
and allowed to keep his ranking points and prize money. 74 Subsequent news
stories reported that the ATP also paid Ulirach an undisclosed sum of money
and agreed to facilitate his entry into tournaments by granting him special wild
75
cards exemptions.
B. Stefan Koubek.
On January 18, 2005, the ITF Independent Anti-Doping Tribunal rendered
a decision in the case of Austrian male professional tennis player Stefan
Koubek ("Koubek"). 76 Koubek has consistently been ranked as one of the top
100 singles players in the world for the last several years. 77 Based on a
positive drug test conducted on May 29, 2004, during the French Open in

66. Id. at
67. Id.

3(4).

68. Id. at
69. Id. at

3(3).
29.

70. Id. at 26. "Equitable estoppel isto be applied as a matter of fairness and good conscience
to estoppe the person whose conduct has brought the situation about from asserting their legal rights
against another party who may have been misled or affected by that conduct." Id.
71. Id. at 28.
72. Id.
73. Id. at 27.
74. Id. at Orders(l). "The orders issued in connection with the Decision of the Tribunal dated 1
I.
May 2003 set out at paragraph 1 herein are hereby withdrawn . " Id.
75. Richard Vach, Agassi, Roddick Rip ATP Leadership, TENNIS X.COM, Feb. 14, 2004,
http://www.tennis-x.com/printstory/2004-02-14/c.php.
76. International Tennis Federation Independent Anti-Doping Tribunal Decision in the Case of
(2005),
http://www.itfiennis.com/shared/medialibrary/pdf/original/
1
Stefan
Koubek,
IO_6137_original.PDF.
77. Id. at

5.
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78
Paris, Koubek was charged with having a glucocorticosteroid in his system.
Koubek did not dispute the presence of the prohibited substance in his system
but did put forth a two-pronged defense. First, Koubek asserted that he bore
"no fault or negligence" for the offense, as defined in the Program. 79 Second,
Koubek posited that his use of the glucocorticosteroid was not intended to
80
enhance his sport performance within the meaning of the Program.
In the hearing, one described by the Tribunal as containing a "considerable
amount of evidence," the Tribunal concluded that Koubek was naive in his
understanding of anti-doping rules but had knowingly agreed to be bound by
81
such rules, as evidenced by his January 5, 2004 signature of a consent form.
At a mandatory ATP player meeting on January 17, 2004, in Melbourne,
Australia, Koubek received informational brochures regarding the Program,
82
but he proceeded to throw them away.
In the spring of 2004, Koubek, a left-handed player, testified that his right
wrist began to hurt, and he sought treatment from an Austrian physician
named Dr. Leixnering in Vienna. 83 Koubek visited Dr. Leixnering's medical
office on May 15, 2004 and received an injection containing an anesthetic and
the prohibited substance. 84 Neither Koubek nor Dr. Leixnering obtained a
theraputic use exemption prior to the injection. 85 Through substantial, but
conflicting testimony from Koubek and Dr. Leixnering the Tribunal concluded
that Dr. Leixnering administered the injection because "[Dr. Leixnering] was
confident that the dose was so low that it would not lead to a positive test
result. 86 Later, after being presented with the testing results, Dr. Leixnering
acknowledged that the injection he administered was the cause of the positive
87
drug test.
With this factual background, the Tribunal concluded that it was obligated
to apply the Program's mandatory sanctions. 88 As such, the Tribunal stripped
Koubek of his 2004 French Open prize money (Euros 35,230) and ATP

78. Id.at

1-2.

79. Id.at 3.
80. Id.
81. Id.at

6, 11.

82. Id. at
83. Id. at

12-13, 15.
17, 19.

84. Id.at TT 27, 29.
85. Id.at 29.
86. Id. at 41.
87. Id. at
88. Id. at

47.
68.
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ranking points (seventy-five entry points and fifteen race points). 8 9 In doing
so, the Tribunal dismissed Koubek's "no fault or negligence" argument but
found that he "succeeded in establishing on the balance of probabilities that
his use of [the glucocorticosteroid] leading to the positive test result was 'not
intended to enhance sport performance." 90 Because the positive test at issue
was Koubek's first offense, the Tribunal exercised its discretion, as allowed
under the Program, and concluded that: (i) Koubek "is not a cheat;" (ii)
Koubek's prize money and ATP ranking points earned in tournaments
following the 2004 French Open should not be disqualified; and (iii) Koubek
should be suspended for a period of three months commencing December 21,
2004. 9 1 On January 31, 2005, Koubek appealed the Tribunal's decision to the
CAS, but he did not find that forum any more friendly, as the CAS dismissed
92
his appeal on March 1, 2005, thereby upholding the decision of the Tribunal.
IV. APPROPRIATENESS OF ADR AS A PART OF THE PROGRAM

The Program's ADR procedures provide the most effective and efficient
means of settling doping disputes. The Program provides many of the same
advantages provided by other ADR proceedings such as the CAS's arbitration
hearings available to Olympic athletes. In addition, the Program provides an
additional safeguard to protect professional tennis players from false claims of
doping.
First, by settling disputes through a hearing before the Tribunal, tennis
players and the applicable tennis governing bodies expend less money.
Generally speaking, ADR proceedings take less time than judicial
proceedings, so they cost the parties less money. 93 The evidentiary rules that
apply in a courtroom are less strictly applied in an ADR proceeding, which
allows for a much quicker procedure. 94 A tennis player is only required to95pay
his or her attorney's fees in connection with a hearing before the Tribunal.
Second, the nature of athletic competition requires quick decisions, which

89. Id. at 144,117.
90. Id. at 91.
112,117.
91. Id.at
92. ITF Tennis, CAS Decision on Koubek Appeal, ITFTENNIS.COM, Mar. 1, 2005,
http://www.itftennis.con/abouttheitf/news/article.asp?id= 3332.
93. JAY E. GRENIG, ALTERNATIVE DISPUTE RESOLUTION WITH FORMS, § 3.2 (2d ed. 2003).
94. Id. The judicial rules of evidence do not apply during hearings before the Anti-Doping
Tribunal. The Code, supra note 4, at 7.06 K.4.
95. The Code states that the tennis governing body is responsible for all costs associated with the
alternative dispute resolution procedures. The Code, supra note 4, at 7.06 K.5.c.
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can be facilitated through ADR procedures. 96 Doping disputes are timesensitive because a positive doping test results in the disqualification of the
athlete from tennis tournaments and can result in the loss of ranking and the
forfeiture of prize money. 97 Likewise, if one player is determined to be
ineligible, then another player could step in and have the opportunity to
compete in a professional tennis tournament, but once the tournament is
played, the opportunity is gone. 98 The Program requires that hearings be held
within sixty days of the date on which the player requested a hearing. 99 The
Tribunal is also instructed to render a decision as quickly as possible after the
hearing. 10 0 The traditional adjudication process in the courts does not provide
for expeditious decisions. For these reasons, lengthy court battles are not an
option for professional tennis players. The tournament is not going to wait for
an athlete's day in court or for a judge to render a decision.
Third, because tennis is an international sport with tournaments held
around the world and athletes from different countries, jurisdictional issues
could frequently arise if disputes were settled in the court systems. In the
Program, parties do not have to worry about conflict of law issues between
various countries.
Fourth, the Program includes a confidentiality safeguard to help protect
the tennis players that come within the purview of its jurisdiction. In order to
protect athletes from the stigma that accompanies a positive doping test, the
Program has a very strict confidentiality policy, which prohibits the public
release of the name of an athlete accused of doping until the Tribunal has
1 1
published its decision or until the player has admitted the doping offense.
In contrast, the WADA Code allows for the public release of information
regarding an alleged anti-doping offense after administrative review
10 2
procedures but prior to an ADR proceeding.
The need for such strict confidentiality became very clear at a tennis
exhibition in December 2004, when fifth ranked Russian Svetlana Kuznetsova
was accused of doping prior to any confirmation by Belgian Sports Minister
Claude Eerdekens. 10 3 Eerdekens announced that a female tennis player who
96. Melissa R. Bitting, Comment, Mandatory, Binding Arbitrationfor Olympic Athletes: Is the
Process Better or Worsefor"Job Security"?, 25 FLA. ST. U. L. REv. 655, 660 (1998).
97. The Code, supra note 4, at 7.06 L, M.
98. Bitting, supra note 96, at 660.
99. The Code, supra note 4, at 7.06 K.l.f..i.
100. Id. at 7.06 K.5.a.
101. Id. at 7.06.Q. 3.
102.

WORLD ANTI-DOPING AGENCY,

WORLD ANTI-DOPING

CODE

art

14,

14.2

(2003),

http://www.wada-ama.org/rtecontent/document/code v3.pdf.
103. Stephen Bierley, Kuznetsova Will Not be Punished,GUARDIAN UNLIMITED, Jan. 19, 2005,
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participated in an exhibition match in Charleroi in December had given a urine
sample that showed traces of ephedrine.I 0 4 Kuznetsova was quickly identified
as the player, and she was forced to answer to the allegations throughout the
2005 Australian Open. 10 5 Ephedrine is not a banned substance under the
Program for players when they are outside of competition. 10 6 The exhibition
match in Belgium was not considered to be in competition; therefore, even if
Kuznetsova had ephedrine in her system, she would not have been in violation
of the Program. 10 7 If the Belgian Sports Minister would have followed the
Program's confidentiality policy, Kuznetsova's alleged violation could have
been dismissed without the media and public ever knowing it existed, and
Kuznetsova could have concentrated exclusively on tennis during the first
Grand Slam tournament of the year. 10 8 WTA and ITF officials offered harsh
criticism of Eerdekens' actions when they stated that it was a "disgraceful and
irresponsible act," and the governing bodies "did not support any disclosure
regarding the identity of any player involved in an adverse anti-doping
finding, unless proper procedures have been followed."' 10 9
Quite the contrary result occurred in the doping controversy involving
British tennis player Greg Rusedski. Rusedski tested positive for nandrolone
at the 2003 RCA Tennis Championships in Indianapolis, Indiana. l l0 This test
was taken in July, only nine months after Bohdan Ulihrach tested positive for
the same substance in Moscow, and one month after the ATP learned of an
electrolyte product being distributed by its trainers, which could have been
causing an abnormally high number of positive doping tests involving
nandrolone. The ATP followed the rules of the Program and refused to
identify or confirm that Rusedski had tested positive. 111 However, Rusedski
went public in an effort to draw attention to the large amount of players testing
positive, stating "[w]e now have over 47 samples (out of 120 top players
http://sport.guardian.co.uk/tennis/story/0,, 1393387,00.html.
104. Afsati Dzhusoiti, They Camefor Kuznetsova, KOMMERSANT: RUSSIA'S DAILY ONLINE, Jan.
18, 2005, http://www.kommersant.com/page.asp?id=539491.
105. Id.
106. Id.
107. Bierley, supra note 103. Kuznetsova admitted to taking a cold remedy prior to the
exhibition match, which could have explained the ephedrine in her system. Id.
108. Kuznetsova was beaten in the quarterfmals by Maria Sharapova. Women's Singles Draw,
EUROSPORT.COM,
http://www.eurosport.com/home/pages/v4/12/s57/e7184/drawjlng2-spo57
_evt7184_gnd2_part2.shtml (last visited Sept. 21, 2005).
109. Bierley, supra note 103.
110. Richard Vach, ATP Could Make an Example ofRusedski Drug Test, TENNIS-X.COM, Jan. 9,
2004, http://www.tennis-x.com/story/2004-01-09/c.php.
111. ATP Response to Greg Rusedski's Statement, ATP.COM,
Jan. 9,
2004,
http://www.atptennis.com/en/common/Tracklt.asp?file=/en/antidoping/Rusedski-Response.pdf.
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tested) demonstrating elevated levels of nandrolone. The odds of this
happening at random are billions to one against." 112 Rusedski was later
exonerated at a hearing before the Tribunal in March 2004.113
The time restraints on the resolution of disputes arising out of doping
offenses and the consequences that could result from a doping charge require a
quick, inexpensive, and confidential dispute resolution procedure. Without the
Program, tennis players could be held out of tournaments needlessly, losing
opportunities for ranking points and prize money.
V. CONCLUSION

The ADR procedures inherent in the Program help make the drug program
in professional tennis effective. It remains to be seen, however, whether the
United States Congress agrees with this conclusion. 114 On April 5, 2005, the
House Government Reform Committee sent a letter to the ATP and the WTA
asking for information concerning their drug-testing policies. 1 15 While the
majority of Congress' attention appears to be devoted to the major North
American team sports of baseball, basketball, and football, the drug programs
in other sports will likely be subject to increased scrutiny as well in the not too
distant future. Until then, the Program will likely continue to meet its twin
goals of ensuring a level playing field and protecting the health of the tennis
players subject to the Program.

112. Vach, supra note 110.
113. Stephen Bierley, Rusedski Drug May Not Have Come From Trainers, Says ATP,
GUARDIAN, Mar. 17, 2004, http://sport.guardian.co.uk/print/0,3858,4881522-108554,00.html.
114. NBA, NHL, MLA, ATP Among Those Queried, ESPN.CoM, Apr. 5, 2005,
http://sports.espn.go.com/espn/news/story?id=2030494.
115. Id.
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